| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 06/23/2005 | CA2546126A1 Use of t-cadherin as a target |
| 06/23/2005 | CA2544018A1 Compositions and methods to reduce mutagenesis |
| 06/23/2005 | CA2543257A1 Methods and compositions for delivering polynucleotides |
| 06/23/2005 | CA2490218A1 Extracorporeal photopheresis in combination with anti-tnf treatment |
| 06/22/2005 | EP1544299A1 Modified chimeric polypeptides with improved pharmacokinetic properties |
| 06/22/2005 | EP1544297A2 Medicament for treatment of Duchenne muscular dystrophy |
| 06/22/2005 | EP1544295A1 Salt-inducible kinases 2 and use thereof |
| 06/22/2005 | EP1544212A1 Modified antiviral proteins with an increased negative charge |
| 06/22/2005 | EP1543839A1 Immunotherapy of autoimmune disorders using antibodies which target B-cells |
| 06/22/2005 | EP1543324A2 Methods and compositions for grafting functional loops into a protein |
| 06/22/2005 | EP1543166A2 Synergistic compositions for the prevention and treatment of acquired immunodeficiency syndrome |
| 06/22/2005 | EP1543161A2 Methods of identifying compounds that modulate il-4 receptor-mediated ige synthesis utilizing a c-myc protein |
| 06/22/2005 | EP1543158A1 Regulated aptamer therapeutics |
| 06/22/2005 | EP1543127A2 Nucleic acid sequences coding for proteolytic enzymes in the form of specific proteases, corresponding polypeptides and use of the same |
| 06/22/2005 | EP1543122A2 Bitter taste receptors |
| 06/22/2005 | EP1543109A2 Substances for preventing and treating autoimmune diseases |
| 06/22/2005 | EP1543037A2 Dendritic cell pontentiation |
| 06/22/2005 | EP1543034A2 Treatment and prophylaxis with 4-1bb-binding agents |
| 06/22/2005 | EP1543030A2 Modified glp-1 peptides with increased biological potency |
| 06/22/2005 | EP1543029A1 Interferon-alpha induced gene |
| 06/22/2005 | EP1543025A2 Human g protein-coupled receptor and modulators thereof for the treatment of ischemic heart disease and congestive heart failure |
| 06/22/2005 | EP1543024A2 Cyclic amp phosphodiesterase 4d7 isoforms and methods of use |
| 06/22/2005 | EP1543023A2 Secondary binding site of dipeptidyl peptidase iv (dp iv) |
| 06/22/2005 | EP1543022A2 Gd2 ligands |
| 06/22/2005 | EP1542768A1 Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| 06/22/2005 | EP1542733A2 Improved method to identify targeting molecules |
| 06/22/2005 | EP1542729A1 Stable immunogenic product comprising antigenic heterocomplexes |
| 06/22/2005 | EP1542728A1 Hybrid of itraconazole, cyclosporine or carvedilol with a layered silicate and a process for preparing the same |
| 06/22/2005 | EP1542722A2 Methods and reagents relating to inflammation and apoptosis |
| 06/22/2005 | EP1542719A2 Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 06/22/2005 | EP1542718A2 Peptide derivative fusion inhibitors of hiv infection |
| 06/22/2005 | EP1542716A1 Growth hormone releasing peptides |
| 06/22/2005 | EP1542715A1 Modulation of immune function |
| 06/22/2005 | EP1542714A1 Methods of increasing platelet and hematopoietic stem cell production |
| 06/22/2005 | EP1542713A2 Skrp, astray, string, vacm associated with metabolic control |
| 06/22/2005 | EP1542712A2 Glp-1 formulations with protracted time action |
| 06/22/2005 | EP1542711A2 PEPTIDES AS SOLUBILIZING EXCIPIENTS FOR TRANSFORMING GROWTH FACTOR s PROTEINS |
| 06/22/2005 | EP1542710A1 Methods for preserving organs and tissues |
| 06/22/2005 | EP1542708A2 Method for treating inflammatory bowel disease |
| 06/22/2005 | EP1542707A2 Compositions and methods for ligament growth and repair |
| 06/22/2005 | EP1542702A2 Methods and compositions for treatment of neurological disorder |
| 06/22/2005 | EP1542609A2 Methods for up-regulating antigen expression in tumors |
| 06/22/2005 | EP1542535A1 Use of proteases for decomposing allergens |
| 06/22/2005 | EP1542528A1 A method of treatment and prophylaxis |
| 06/22/2005 | EP1381611B1 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| 06/22/2005 | EP1267915B1 Activated protein c for treating pancreatitis |
| 06/22/2005 | EP1244693B1 Compositions for treating abnormalities in glomerular filtration, patent ductus arteriosus and osteoporosis |
| 06/22/2005 | EP1212078B1 Ant-1 as drug target |
| 06/22/2005 | EP1196188B1 Vgf selective monoclonal antibodies and their use for treating vgf-related disorders |
| 06/22/2005 | EP1150717B1 Sustained release salts of pharmaceutically active peptides and their production |
| 06/22/2005 | EP1100542B1 Peg-urate oxidase conjugates and use thereof |
| 06/22/2005 | EP1082127B1 Succinamide inhibitors of interleukin-1beta converting enzyme |
| 06/22/2005 | EP1073465B1 T cell inhibitory receptor compositions and uses thereof |
| 06/22/2005 | EP1009411B1 Treatment of sleep apnea |
| 06/22/2005 | EP1007533B1 Bioconjugates and delivery of bioactive agents |
| 06/22/2005 | EP0927254B1 Antagonists of interleukin-15 |
| 06/22/2005 | EP0892644B1 In vivo gene transfer methods for wound healing |
| 06/22/2005 | EP0870509B1 Sugar chain-recognizing antibody and remedy for infection with hiv |
| 06/22/2005 | CN1630819A Renal cell carcinoma markers |
| 06/22/2005 | CN1630818A Diagnostic markers for ischemia |
| 06/22/2005 | CN1630728A Buffer solution for electroporation and a method comprising the use of the same |
| 06/22/2005 | CN1630726A Beta-lactamase/anminoglycosides modifying enzyme genes, their fusion gene and the expression products, the composition thereof, and their uses in medicine and environmental protection |
| 06/22/2005 | CN1630724A Compositions and methods for inhibiting expression of a target gene |
| 06/22/2005 | CN1630721A Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia |
| 06/22/2005 | CN1630720A Bifunctional fusion proteins with glucocerebrosidase activity |
| 06/22/2005 | CN1630709A Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| 06/22/2005 | CN1630708A Osteoclast-associated receptor |
| 06/22/2005 | CN1630666A Factor VIII2 C2 domain variants |
| 06/22/2005 | CN1630664A Caspase-8 binding protein, its preparation and use |
| 06/22/2005 | CN1630663A Synthetic or natural peptides binding protein phosphatase 2A, identification method and uses |
| 06/22/2005 | CN1630635A Amino alcohol derivatives or phosphonic acid derivatives and pharmaceutical compositions containing these |
| 06/22/2005 | CN1630538A Stimulation of vascularization with VEGF-B |
| 06/22/2005 | CN1630535A Inhibition of STAT-1 |
| 06/22/2005 | CN1630532A Methods for prevention and treatment of gastrointestinal disorders |
| 06/22/2005 | CN1630530A Polyalkylene polymer compounds and uses thereof |
| 06/22/2005 | CN1630529A B-cell lymphoma specific antigen for use in diagnosis and treatment of B-cell malignancies |
| 06/22/2005 | CN1630527A Methods and compositions for oxygen transport comprising a high oxygen affinity |
| 06/22/2005 | CN1630526A Systems and methods for treating patients with processed lipoaspirate cells |
| 06/22/2005 | CN1630521A Oral compositions and methods for prevention, reduction and treatment of radiation injury |
| 06/22/2005 | CN1630518A Methods of treating and preventing bone loss |
| 06/22/2005 | CN1630516A Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents |
| 06/22/2005 | CN1630514A Methods and compositions for control of bone formation via modulation of sympathetic tone |
| 06/22/2005 | CN1629309A Method for screening acceptor blocker for controlling prawn virus infection |
| 06/22/2005 | CN1629288A Recombinant Baculovirus for expressing CTB and human insulin fusion protein and use thereof |
| 06/22/2005 | CN1629190A A protein, gene and pharmaceutical use thereof |
| 06/22/2005 | CN1629186A Ganoderma lucidum polysaccharide protein and its preparing method and use |
| 06/22/2005 | CN1629185A Fusion proteins of mycobacterium tuberculosis antigens and their uses |
| 06/22/2005 | CN1628845A Compound medicinal formulation with bioactivity |
| 06/22/2005 | CN1628844A Method for extending in vivo half life of protein medicine by making red cell as carrier |
| 06/22/2005 | CN1628843A Technology for preparing capsule of liver cell growth promoting factor |
| 06/22/2005 | CN1628842A Composition for treating virus infection |
| 06/22/2005 | CN1628841A Composition for treating virus infection |
| 06/22/2005 | CN1207387C Polypeptides and genes encoding same |
| 06/22/2005 | CN1207306C Peptide compound for preventing and treating HIV infection and immunity diseases |
| 06/22/2005 | CN1207305C Preparing process and application of recombinant human interleukin-11 |
| 06/22/2005 | CN1207302C Method and compounds for curing diseases caused by mutations |
| 06/22/2005 | CN1207288C Retroviral protease inhibiting compounds |
| 06/22/2005 | CN1207056C Peptide-containing & alpha; -ketoamide cysteine and serine protease inhibitors |
| 06/22/2005 | CN1206982C Stable protein: phospholipid compositions and methods |
| 06/22/2005 | CN1206921C Antimicrobial composition comprising an oxidoreductase and an enhancing agent of the N-hydroxy anilide-type |